Craig-Hallum Maintains Buy on Avid Bioservices, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Matt Hewitt has maintained a Buy rating on Avid Bioservices (NASDAQ:CDMO) but has reduced the price target from $22 to $16.

December 08, 2023 | 5:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avid Bioservices' stock may experience a short-term negative impact due to the lowered price target from $22 to $16 by Craig-Hallum, despite maintaining a Buy rating.
The reduction in price target by a respected analyst can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals, which may mitigate the impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100